

THE ONLY ONCE-DAILY ORAL PREVENTIVE
CGRP RECEPTOR ANTAGONIST¹

TURN ON QUICK AND CONTINUOUS MIGRAINE PREVENTIVE POWER WITH QULIPTA™



ONE PILL, ONCE A DAY¹
No titration needed¹
No injections

(See dosage adjustments on back.)



QULIPTA
60 mg



QULIPTA
30 mg



QULIPTA
10 mg



Across a 12-week clinical trial
(QULIPTA 60 mg)*:

- > Significant 54% migraine day reduction (4.2 mean MMD reduction from 7.8 baseline)[†] vs 33% (2.5 mean MMD reduction from 7.5 baseline) with placebo^{‡§}
- > With the majority of impact observed within Weeks 1-4^{1,2}
- > Over 60% of patients cut their migraine days by at least half[†] vs 29% for placebo^{‡§}

*Data from the Phase 3 ADVANCE trial.

[†]QULIPTA 60 mg (n=222).

[‡]Placebo (n=214).

[§]P<0.001.

MMD=Monthly Migraine Day

Phase 2b/3 Dose-finding Study Results:

QULIPTA 60 mg: -3.6 monthly migraine days across 12 weeks (baseline MMD was 7.7) (n=177) (P=0.039).
Placebo: -2.8 monthly migraine days across 12 weeks (baseline MMD was 7.8) (n=178).¹

Study Design

Two randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 4 to 14 migraine days per month. Patients in trials were 88% female, 80% White, 17% Black, and 12% Hispanic or Latino ethnicity and the mean age at study entry was 41 years (range 18-74 years).¹

INDICATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

Please see additional Important
Safety Information on next page
and full Prescribing Information at
rxabbvie.com/pdf/QULIPTA_pi.pdf.

QULIPTA™
(atogepant) tablets

QULIPTA™ — PREVENTIVE POWER THAT HAS YOUR MIGRAINE PATIENTS COVERED¹

RECOMMENDED DOSAGE:

- > 10 mg, 30 mg, or 60 mg orally once daily

DOSAGE ADJUSTMENT:

- > **Concomitant Strong and Moderate CYP3A4 Inducers:**
Recommended dose is 30 mg or 60 mg once daily
- > **Concomitant OATP Inhibitors:**
Recommended dose is 10 mg or 30 mg once daily
- > **Severe Renal Impairment:**
Recommended dose is 10 mg once daily
- > **Concomitant Strong CYP3A4 Inhibitors:**
Recommended dose is 10 mg once daily
- > **End-Stage Renal Disease:**
Recommended dose is 10 mg once daily

Avoid use in patients with severe hepatic impairment.

INDICATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

Please see additional Important Safety Information on previous page and full Prescribing Information at rxabbvie.com/pdf/QULIPTA_pi.pdf.

References: 1. QULIPTA (atogepant). Package insert. Allergan USA, Inc; 2021. 2. Data on file. Allergan USA, Inc.



Scan for more information about QULIPTA dosing.

QULIPTA™ and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.
© 2022 AbbVie. All rights reserved.
US-QLP-220050 04/22

 **QULIPTA**™
(atogepant) tablets